Ascendis Pharma (NASDAQ: ASND) adds shares after warrant exercises
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Ascendis Pharma A/S reports the closing of an exercise window for its outstanding warrants linked to ordinary shares. During this period, warrant holders exercised rights resulting in registered share capital increases of nominal DKK 399,438, bringing total share capital to nominal DKK 62,376,846.
The company issued 399,438 new ordinary shares against average cash consideration of approximately USD $92.10 per share, based on the DKK-USD exchange rate on March 30, 2026. Ascendis amended its articles of association to reflect the higher share capital, and the updated articles are attached as an exhibit.
Positive
- None.
Negative
- None.
Key Figures
New shares issued: 399,438 shares
Capital increase: DKK 399,438 nominal
Total share capital: DKK 62,376,846 nominal
+1 more
4 metrics
New shares issued
399,438 shares
Issued upon warrant exercises during the exercise window
Capital increase
DKK 399,438 nominal
Increase in registered share capital from warrant exercises
Total share capital
DKK 62,376,846 nominal
Total nominal share capital after registration of increases
Average consideration per share
USD $92.10 per share
Average cash consideration based on DKK-USD rate on March 30, 2026
Key Terms
Form 6-K, warrants, Articles of Association, registration statements on Form S-8, +1 more
5 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
warrants financial
"an exercise window closed for the Company’s outstanding warrants exercisable"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Articles of Association regulatory
"The Company’s articles of association were amended accordingly and are attached"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
registration statements on Form S-8 regulatory
"incorporated by reference into the registration statements on Form S-8"
Form F-3 regulatory
"and Form F-3 (Registration Numbers 333-209336 and 333-282196)"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
FAQ
What did Ascendis Pharma A/S (ASND) announce in this Form 6-K?
Ascendis Pharma A/S announced that a warrant exercise window closed and certain outstanding warrants were exercised. This led to new ordinary shares being issued, an increase in nominal share capital, and amendments to the company’s articles of association to reflect the updated capital structure.
How were Ascendis Pharma A/S’s articles of association affected by the warrant exercises?
Ascendis Pharma A/S amended its articles of association to incorporate the increased nominal share capital after the warrant exercises. The updated articles, reflecting the new total nominal share capital of DKK 62,376,846, are provided as Exhibit 1.1 and form part of the report’s documentation.
Are Ascendis Pharma A/S’s existing registration statements affected by this Form 6-K?
Yes. This Form 6-K is incorporated by reference into Ascendis Pharma A/S’s existing registration statements on Form S-8 and Form F-3. It becomes part of those registration statements from the filing date, unless later documents or reports supersede the information contained here.